Cargando…

P411: LONGITUDINAL CHARACTERIZATION OF MOLECULAR VARIANTS AT REMISSION AND RELAPSE: SUBANALYSIS OF THE QUAZAR AML-001 TRIAL

Detalles Bibliográficos
Autores principales:	Lopes De Menezes, Daniel, Wei, Andrew, Döhner, Hartmut, Roboz, Gail, Teresa Voso, Maria, Schuh, Andre, See, Wendy L., Ugidos, Manuel, Amzallag, Arnaud, Risueño, Alberto, Kyriakopoulos, Charalampos, Nvs Suragani, Rajasekhar, Skikne, Barry, Beach, CL, Prebet, Thomas, Gandhi, Anita
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428725/ http://dx.doi.org/10.1097/01.HS9.0000968552.93087.6b

Ejemplares similares

P459: DISEASE MONITORING OF NPM1-MUTANT (MUT) ACUTE MYELOID LEUKEMIA (AML) USING MEASURABLE RESIDUAL DISEASE (MRD) ASSESSMENTS DURING ORAL AZACITIDINE (ORAL-AZA) TREATMENT (TX): A QUAZAR AML-001 SUBANALYSIS
por: Lopes De Menezes, Daniel, et al.
Publicado: (2023)

Survival outcomes with oral azacitidine maintenance in patients with acute myeloid leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase III QUAZAR AML-001 trial
por: Wei, Andrew H., et al.
Publicado: (2023)

Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial
por: Ravandi, Farhad, et al.
Publicado: (2021)

Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia
por: Roboz, Gail J, et al.
Publicado: (2016)

Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase III, placebo-controlled QUAZAR AML-001 trial
por: Roboz, Gail J., et al.
Publicado: (2021)

Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine
por: Döhner, Hartmut, et al.
Publicado: (2022)

Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion–dependent anemia and thrombocytopenia
por: Garcia-Manero, Guillermo, et al.
Publicado: (2016)

P693: LUSPATERCEPT RESTORES EFFECTIVE ERYTHROPOIESIS AND PROVIDES SUPERIOR AND SUSTAINED CLINICAL BENEFIT VS EPOETIN ALFA: BIOMARKER ANALYSIS FROM THE PHASE 3 COMMANDS STUDY
por: Platzbecker, Uwe, et al.
Publicado: (2023)

P697: DISTINCT SPLICING ALTERATIONS ASSOCIATED WITH CLINICAL RESPONSE TO LUSPATERCEPT IN PATIENTS WITH LOWER‑RISK MYELODYSPLASTIC SYNDROMES FROM THE MEDALIST STUDY
por: Aluri, Srinivas, et al.
Publicado: (2023)

P997: FEDRATINIB IS EFFECTIVE IN RUXOLITINIB-RESISTANT CELLS: CLINICAL AND PRECLINICAL CORRELATIONS
por: Jeyaraju, Danny, et al.
Publicado: (2023)

411 Mrd. €, 11,9 %
por: Kuhn, Joseph
Publicado: (2022)

Route 411 to Cardiac Regeneration
por: Van den Bogaert, Siel, et al.
Publicado: (2022)

P440: ENHANCER HIJACKING IN COMPLEX-KARYOTYPE AML
por: Sollier, Etienne, et al.
Publicado: (2023)

MRD in AML: The Role of New Techniques
por: Voso, Maria Teresa, et al.
Publicado: (2019)

getITD for FLT3-ITD-based MRD monitoring in AML
por: Blätte, Tamara J., et al.
Publicado: (2019)

PHL4/411: Getting Practice on the Internet
por: G. Neville, R, et al.
Publicado: (1999)

Memorandum: requests for R411 running conditions
por: CERN. Geneva. Intersecting Storage-Rings Committee
Publicado: (1975)

Secondary mutations in t(4;11) leukemia patients
por: Prelle, C, et al.
Publicado: (2013)

Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal
por: Estey, Elihu, et al.
Publicado: (2022)

AML consolidation therapy: timing matters
por: Reimann, Adrian-Manuel, et al.
Publicado: (2023)

411 The Classification of Allergic Rhinitis and Its Cytological Correlate
por: Gelardi, Matteo, et al.
Publicado: (2012)

Comparative analysis of pulmonary and extrapulmonary tuberculosis of 411 cases
por: Sunnetcioglu, Aysel, et al.
Publicado: (2015)

The RS4;11 cell line as a model for leukaemia with t(4;11)(q21;q23): Revised characterisation of cytogenetic features
por: Ragusa, Denise, et al.
Publicado: (2019)

Risk of infection in elderly patients with AML and MDS treated with hypomethylating agents
por: Livio, Pagano, et al.
Publicado: (2018)

IS411: Coulomb Excitation of neutron-rich A~140 Nuclei
por: Kröll, Thorsten
Publicado: (2015)

Synthesis of amorpha-4,11-diene from dihydroartemisinic acid
por: Schwertz, Geoffrey, et al.
Publicado: (2019)

411. Tolerability of Isavuconazole After Posaconazole Toxicity in Leukemia Patients
por: DiPippo, Adam J, et al.
Publicado: (2018)

411 The Hatchery, a Universal Approach for Incubator Space in Academia
por: Hale, Rena, et al.
Publicado: (2023)

Case of Patient with AML with Complex Karyotype including Ultra-Rare t(4;8)(q32;q13), t(4;11)(q21;p15) and Familial Aggregation of Myeloid Malignancies
por: Milczarek, Sławomir, et al.
Publicado: (2022)

A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML
por: Zeidan, Amer M., et al.
Publicado: (2022)

Acquired TET2 mutation in one patient with familial platelet disorder with predisposition to AML led to the development of pre‐leukaemic clone resulting in T2‐ALL and AML‐M0
por: Manchev, Vladimir T., et al.
Publicado: (2016)

5,5,7,12,14,14-Hexamethyl-1,8-diaza-4,11-diazoniacyclotetradeca-4,11-diene dichloride trihydrate
por: Ismail, Wafiuddin, et al.
Publicado: (2012)

Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS
por: List, A F, et al.
Publicado: (2014)

Following 411 Cochrane Protocols to Completion: A Retrospective Cohort Study
por: Tricco, Andrea C., et al.
Publicado: (2008)

Complications of 411 laparoscopic urological procedures: A single surgeon experience
por: Al-Otaibi, Khalid
Publicado: (2018)

Substitution of PINK1 Gly411 modulates substrate receptivity and turnover
por: Fiesel, Fabienne C, et al.
Publicado: (2022)

Erratum: Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS
por: List, A F, et al.
Publicado: (2015)

Real-World Treatment Patterns and Clinical Outcomes in Korean Patients With AML Ineligible for First-Line Intensive Chemotherapy: A Subanalysis of the CURRENT Study, a Non-Interventional, Retrospective Chart Review
por: Bang, Soo-Mee, et al.
Publicado: (2023)

Treatment of Low-Blast Count AML using Hypomethylating Agents
por: De Bellis, Eleonora, et al.
Publicado: (2017)

Heterodimerization of AML1/ETO with CBFβ is required for leukemogenesis but not for myeloproliferation
por: Thiel, V N, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_gu2n6k6bc2e8jnpem065p97g3p